[go: up one dir, main page]

AR057218A1 - Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato - Google Patents

Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato

Info

Publication number
AR057218A1
AR057218A1 ARP060105350A ARP060105350A AR057218A1 AR 057218 A1 AR057218 A1 AR 057218A1 AR P060105350 A ARP060105350 A AR P060105350A AR P060105350 A ARP060105350 A AR P060105350A AR 057218 A1 AR057218 A1 AR 057218A1
Authority
AR
Argentina
Prior art keywords
alkylene
alkyl
nr4r5
heterocycloalkyl
cycloalkyl
Prior art date
Application number
ARP060105350A
Other languages
English (en)
Inventor
Abdelmalik Slassi
Joseph Babu
Ma Fupeng
Ian Egle
Joshua Clayton
Isaac Methvin
Krzysztof Swierczek
Original Assignee
Astra Ab
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab, Nps Pharma Inc filed Critical Astra Ab
Publication of AR057218A1 publication Critical patent/AR057218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas que contienen los compuestos, y uso de los mismos en trastornos neurologicos y psiquiátricos. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) donde: R1 se selecciona del grupo que consiste en H, hidroxilo, F, Cl, Br, I, nitro, CN, alquilo, alquilhalo, O-alquilo, O-alquilhalo, alquenilo, O-alquenilo, alquinilo, O-alquinilo, cicloalquilo, alquilen-ciclo-alquilo, O-cicloalquilo, O-alquilen-cicloalquilo, heterocicloalquilo, alquilen- heterocicloalquilo, O-heterocicloalquilo, O-alquilen-heterocicloalquilo, arilo, alquilenarilo, O-arilo, O-alquilenarilo, heteroarilo, alquilenheteroarilo, O-heteroarilo, O-alquilenheteroarilo, (CO)cicloalquilo, (CO)heterocicloalquilo, (CO)arilo, (CO)heteroarilo, alquilenOR4, O-alquilenOR4, (CO)R7, O(CO)R7, alquilenO(CO)R7, alquilen(CO)R7, O-alquilen(CO)R7, CO2R7, alquilenCO2R7, O-alquilenCO2R7, alquilenciano, O-alquilenciano, NR4R5, alquilenNR4R5, O-alquilenNR4R5, (CO)NR4R5, alquilen(CO)NR4R5, O-(CO)NR4R5, O-alquilen(CO)NR4R5, NR4(CO)R3, alquilenNR4(CO)R3, O-alquilenNR4(CO)R5, NR4(CO)NR4R5, alquilenNR4(CO)NR4R5, SR4, alquilenSR4, O-alquilenSR4, (SO)R3, alquilen(SO)R3, O-alquilen(SO)R3, SO2R3, alquilenSO2R3, O- alquilenSO2R3, (SO)2NR4R5, alquilen(SO)2NR4R5, O-alquilen(SO)2NR4R5, NR4(SO)2R5, alquilenNR4(SO)2R5, O-alquilenNR4(SO)2R5, NR4(SO)2NR4R5, alquilenNR4(SO)2NR4R5, O-alquilenNR4(SO)2NR4R5, NR4OR5, NR4(CO)OR7, alquilNR4(CO)OR7, O-alquilNR4(CO)OR7, y cualquier porcion cíclica está opcionalmente sustituida con uno o más sustituyentes R6 seleccionados independientemente; R2 se selecciona del grupo que consiste en H, hidroxilo, F, Cl, Br, I, CN, alquilo, alquilhalo, O-alquilo, O-alquilhalo, cicloalquilo, alquilen-cicloalquilo, O-cicloalquilo, O-alquilen-cicloalquilo, heterocicloalquilo, alquilen-heterocicloalquilo, O-heterocicloalquilo, O-alquilen-heterocicloalquilo, arilo, alquilenarilo, O-arilo, O-alquilenarilo, heteroarilo, alquilenheteroarilo, O-heteroarilo, O-alquilenheteroarilo, alquilenOR4, O-alquilenOR4, (CO)R7, alquilen(CO)R7, alquilenNR4R5, O-alquilenNR4R5, (CO)NR4R5, alquilen(CO)NR4R5, O-alquilen(CO)NR4R5, alquilenNR4(CO)R3, y cualquier porcion cíclica está opcionalmente sustituida con uno o más sustituyentes R6 seleccionados independientemente; R3, en cada caso, se selecciona del grupo que consiste en H y alquilo; R4 y R5 se seleccionan independientemente del grupo que consiste en H, alquilo, alquilhalo, alquenilo, alquinilo, cicloalquilo, alquilencicloalquilo, heterocicloalquilo, alquilenheterocicloalquilo, arilo, alquilenarilo, heteroarilo, y alquilenheteroarilo, NR7R8, alquilenNR7R8, OR7, alquilenOR7, y cualquier porcion cíclica está opcionalmente sustituida con un sustituyente seleccionado del grupo que consiste en alquilo, halo, haloalquil, O-alquilo, O-haloalquilo, arilo, alquilenarilo, heteroarilo y alquilenheteroarilo; R6, en cada caso, se selecciona del grupo que consiste en H, hidroxilo, F, Cl, Br, I, nitro, CN, oxo, alquilo, alquilhalo, O-alquilo, O-alquilhalo, alquenilo, O-alquenilo, alquinilo, O-alquinilo, cicloalquilo, alquilen-cicloalquilo, O-cicloalquilo, O-alquil-cicloalquilo, heterocicloalquilo, alquilen- heterocicloalquilo, O-heterocicloalquilo, O-alquilen-heterocicloalquilo, arilo, alquilenarilo, O-arilo, O-alquilenarilo, heteroarilo, alquilenheteroarilo, O-heteroarilo, O-alquilenheteroarilo, (CO)cicloalquilo, (CO)heterocicloalquilo, (CO)arilo, (CO)heteroarilo, alquilenOR4, O-alquilenOR4, (CO)R3, O(CO)R3, alquilenO(CO)R3, alquilen(CO)R3, O-alquilen(CO)R3, CO2R4, alquilenCO2R3, O-alquilenCO2R3, alquilenciano, O-alquilenciano, NR4R5, alquilenNR4R5, O-alquilenNR4R5, (CO)NR4R5, alquilen(CO)NR4R5, O-(CO)NR4R5, O-alquilen(CO)NR4R5, NR4(CO)R3, alquilenNR4(CO)R3, O-alquilenNR4(CO)R3, NR4(CO)NR4R13, SR4, alquilenSR5, O-alquilenSR4, (SO)R3, alquilen(SO)R3, O-alquilen(SO)R3, SO2R3, alquilenSO2R3, O-alquilenSO2R3, (SO2)NR4R5, alquilen(SO2)NR4R5, O-alquilen(SO2)NR7R8, NR7(SO2)R8, alquilenNR7(SO2)R8, O-alquilenNR4(SO2)R5, NR4(CO)OR5, alquilNR4(CO)OR5, O-alquilNR4(CO)OR5, SO3R4, y cualquier porcion cíclica está opcionalmente sustituida con un sustituyente seleccionado del grupo que consiste en halo, alquilo, O-alquilo haloalquilo, O-haloalquilo y NR4R5; R7 y R8 se seleccionan independientemente del grupo que consiste en H y alquilo; Y se selecciona del grupo que consiste en alquileno, alquenileno y alquinileno, donde cualquier átomo de H de Y puede estar sustituido independientemente con uno o más sustituyentes seleccionados del grupo que consiste en hidroxilo, F, Cl, Br, I alquilo, alquilhalo y O-alquilo; y m y n se seleccionan independientemente del grupo que consiste en 0, 1, 2, 3 y 4; con la condicion de que el compuesto no se selecciona del grupo que consiste en: 3-bencil-5-fenil-2-oxazolidinona; 3-(alfa-metil-(4-metilbencil))-5-fenil-2-oxazolidinona; 3-((2-tienil)metil)-5-fenil-2-oxazolidinona; 5- (3,4-dimetoxifenil)-3-bencil-2-oxazolidinona; 5-(3,4-dimetoxifenil)-3-(2-(3,4-dimetoxifeniletil))-2-oxazolidinona; 4[2-[5-(3-clorofenil)-2-oxazolidin-3-il]propil]fenoxi etanoato de metilo; ácido 4[2-[5-(3-clorofenil)-2-oxazolidin-3-il]propil]fenoxi etanoico, 3-[1-(4-metilfenil)etil]-5-fenil-2-oxazolidinona; 5-(3-clorofenil)-3-(2-(3,4-dihidroxifenil)-1-metiletil)-2-oxazolidinona y 5-(3-clorofenil)-3-[(3,4-dimetoxifenil)-butan-2-il]-2-oxazolidinona.
ARP060105350A 2005-12-15 2006-12-04 Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato AR057218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75034705P 2005-12-15 2005-12-15

Publications (1)

Publication Number Publication Date
AR057218A1 true AR057218A1 (es) 2007-11-21

Family

ID=38030087

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105350A AR057218A1 (es) 2005-12-15 2006-12-04 Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato

Country Status (8)

Country Link
US (2) US20090012089A1 (es)
EP (1) EP1994016A2 (es)
JP (1) JP2009519929A (es)
CN (1) CN101426773A (es)
AR (1) AR057218A1 (es)
TW (1) TW200732313A (es)
UY (1) UY29988A1 (es)
WO (1) WO2007078523A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
JP4827986B2 (ja) 2007-06-08 2011-11-30 マンカインド コーポレ−ション ＩＲＥ−１αインヒビター
WO2009004430A1 (en) * 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
NZ584148A (en) 2007-09-14 2011-05-27 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
WO2009094265A1 (en) * 2008-01-24 2009-07-30 Merck & Co., Inc. 3,5-substituted-1,3-oxazolidin-2-one derivatives
US20090325964A1 (en) * 2008-05-23 2009-12-31 Wyeth Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
ES2466341T3 (es) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
GB201002563D0 (en) * 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
AU2011303597A1 (en) 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
KR20130119964A (ko) * 2010-12-22 2013-11-01 퍼듀 퍼머 엘피 나트륨 채널 차단제로서의 치환된 피리딘
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
DK3096790T3 (da) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
KR20220038826A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) * 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186126A (en) * 1978-04-11 1980-01-29 Messick John J Sulfonate antioxidants for synthetic and natural rubber
DD153682A1 (de) * 1978-10-19 1982-01-27 Horst Bercher Verfahren zur herstellung neuer alkanolamine
DE3438839A1 (de) 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische praeparate
HU203330B (en) 1987-06-10 1991-07-29 Pfizer Process for producing oxazolidin-2-one derivatives and hypoglychemic pharmaceutical compositions containing them
JP2782105B2 (ja) * 1990-02-14 1998-07-30 曙ブレーキ工業株式会社 ノンアスベストス摩擦材
US5106867A (en) 1990-05-04 1992-04-21 American Cyanamid Company Method of increasing lean meat in edible animals
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5574030A (en) * 1992-07-14 1996-11-12 Nippon Chemiphar Co., Ltd. N-aminoalkyl-substituted nitrogen-containing five membered heterocyclic compounds
EP0579169B1 (en) 1992-07-14 1998-09-02 Nippon Chemiphar Co., Ltd. Alkylenediamine derivatives
TW280812B (es) * 1993-07-02 1996-07-11 Bayer Ag
US5482971A (en) * 1993-10-01 1996-01-09 American Cyanamid Company Beta3 -adrenergic agents and their use in pharmaceutical compositions
US5420291A (en) * 1993-12-09 1995-05-30 American Cyanamid Company Process improvement in the synthesis of [R-(R*,R*)1-5-(3-chlorophenyl)-3-[2-]-2-oxazolidinone
DE69404269T2 (de) 1993-12-09 1997-10-30 American Cyanamid Co Verbesserung bei der Herstellung [R-(R*, R*)]-5-(3-chlorophenyl)-3-(2-(3,4-dihydroxyphenyl)-1-methylethyl-2-Oxazolidinone
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
CA2188269A1 (en) 1994-04-21 1995-11-02 Helmut Wachtel Pde iv inhibitors for treating multiple sclerosis
US5461163A (en) * 1994-06-06 1995-10-24 American Cyanamid Company Synthesis and purification of [R-(R*,R*)]-5-[2-[5-(3-chloro-phenyl)-2-oxo-3-oxazolidinyl]-propyl]-1,-3-benzodiozole-2,2-dicarboxylic acid dimethyl ester
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
AU706159B2 (en) * 1995-02-10 1999-06-10 Schering Aktiengesellschaft Pharmaceutical preparations for TNF inhibition
IT1274571B (it) * 1995-05-25 1997-07-17 Fabbrica Italiana Sintetici Spa Procedimento per la preparazione di ¬r-(r*,r*)|-5-(3-clorofenil)-3- ¬2-(3,4-dimetossifenil)-1-metil-etil|-ossazolidin-2-one
JPH09268171A (ja) * 1996-04-03 1997-10-14 Sumika Fine Chem Kk 光学活性オキサゾリジノン誘導体の製造方法
JPH1036359A (ja) 1996-07-22 1998-02-10 Sumitomo Chem Co Ltd ５−（３−クロロフェニル）−３−〔２−（３，４−ジメトキシフェニル）−１−メチルエチル〕−２−オキサゾリジノンの製造方法
US5965607A (en) * 1996-12-30 1999-10-12 American Home Products Corporation Substituted Benzo[1,4]dioxines as antiobesity agents
CA2271885A1 (en) 1996-12-30 1998-07-09 American Home Products Corporation Substituted benzo[1,4]dioxanes as antiobesity agents
JPH1135534A (ja) 1997-07-17 1999-02-09 Sawai Seiyaku Kk フェノキシ酢酸誘導体
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
AUPP796798A0 (en) * 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2001072723A1 (en) * 2000-03-28 2001-10-04 Nippon Soda Co.,Ltd. Oxa(thia)zolidine derivative and anti-inflammatory drug
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
EP1389185A2 (en) * 2001-05-24 2004-02-18 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
JP2004534772A (ja) * 2001-05-24 2004-11-18 藤沢薬品工業株式会社 アミノアルコール誘導体
WO2003031414A1 (en) 2001-10-03 2003-04-17 Nippon Soda Co.,Ltd. Novel heterocyclic compound and anti-inflammatory agent
MXPA05006657A (es) 2002-12-23 2005-08-16 Hoffmann La Roche Oxazoles como potenciadores de los receptores de glutamato metabotropicos 1 (mglu1).
TWI301760B (en) * 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
KR100890886B1 (ko) * 2005-02-24 2009-03-31 니혼노야쿠가부시키가이샤 신규 할로알킬설폰아닐리드 유도체, 제초제 및 이의 이용방법

Also Published As

Publication number Publication date
WO2007078523A3 (en) 2007-11-15
TW200732313A (en) 2007-09-01
JP2009519929A (ja) 2009-05-21
US20070275966A1 (en) 2007-11-29
WO2007078523A2 (en) 2007-07-12
UY29988A1 (es) 2007-07-31
US20090012089A1 (en) 2009-01-08
CN101426773A (zh) 2009-05-06
EP1994016A2 (en) 2008-11-26
US7816354B2 (en) 2010-10-19

Similar Documents

Publication Publication Date Title
AR057218A1 (es) Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
AR035523A1 (es) Uso de compuestos de aminoacetonitrilo para combatir animales daninos endoparasitarios en animales utiles y domesticos de sangre caliente
PE20120229A1 (es) Compuestos heterociclicos como inhibidores de proteasa aspartica
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
ECSP077178A (es) Agentes herbicidas
PE20060417A1 (es) Indazoles como moduladores de lxrs
AR068074A1 (es) Compuestos de piperazina con accion herbicida. proceso de preparacion
AR059516A1 (es) Derivados de isoxazolina, procesos de obtencion y composiciones herbicidas
ES2530431T3 (es) Compuestos heterocíclicos como moduladores positivos del receptor de glutamato metabotrópico 2 (receptor mGlu2)
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
AR067663A1 (es) Derivados heterociclicos de etiloxi amidas, composiciones que los comprenden y usos de los mismos en agricultura u horticultura, como agentes antifungicos.
PE20120656A1 (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos
AR074696A1 (es) Derivados heterociclicos de isoxazol para su uso como reguladores del crecimiento de plantas.
AR068075A1 (es) Compuestos de piperazina con accion herbicida. proceso de preparacion
AR064355A1 (es) Herbicidas derivados de isoxazol
ATE513546T1 (de) Imidazolidin-derivate, ihre verwendungen, ihre zubereitung und diese enthaltende zusammensetzungen
AR073136A1 (es) Compuestos de pirrol
PE20091444A1 (es) Derivados de isoxazolo-pirazina
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
CO6140056A2 (es) Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa
AR073487A1 (es) Diaminopirimidinas 4- alquil sustituidas
CO5631434A2 (es) Derivados de piridina-carboxamida y su uso como plaguicidas
PE20091490A1 (es) Derivados sustituidos de indol

Legal Events

Date Code Title Description
FB Suspension of granting procedure